About: In Vitro Activity of Sodium New Houttuyfonate Alone and in Combination with Oxacillin or Netilmicin against Methicillin-Resistant Staphylococcus aureus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: In Vitro Activity of Sodium New Houttuyfonate Alone and in Combination with Oxacillin or Netilmicin against Methicillin-Resistant Staphylococcus aureus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	In Vitro Activity of Sodium New Houttuyfonate Alone and in Combination with Oxacillin or Netilmicin against Methicillin-Resistant Staphylococcus aureus
Creator	Jiang, Jiandong Lu, Xi Li, Xue Hu, Xinxin Lu, Yun Ren, Zhitao Yang, Xinyi You, Xuefu Zhao, Longyin
source	Medline; PMC
abstract	BACKGROUND: Staphylococcus aureus can cause severe infections, including bacteremia and sepsis. The spread of methicillin-resistant Staphylococcus aureus (MRSA) highlights the need for novel treatment options. Sodium new houttuyfonate (SNH) is an analogue of houttuynin, the main antibacterial ingredient of Houttuynia cordata Thunb. The aim of this study was to evaluate in vitro activity of SNH and its potential for synergy with antibiotics against hospital-associated MRSA. METHODOLOGY: A total of 103 MRSA clinical isolates recovered in two hospitals in Beijing were evaluated for susceptibility to SNH, oxacillin, cephalothin, meropenem, vancomycin, levofloxacin, minocycline, netilmicin, and trimethoprim/sulfamethoxazole by broth microdilution. Ten isolates were evaluated for potential for synergy between SNH and the antibiotics above by checkerboard assay. Time-kill analysis was performed in three isolates to characterize the kill kinetics of SNH alone and in combination with the antibiotics that engendered synergy in checkerboard assays. Besides, two reference strains were included in all assays. PRINCIPAL FINDINGS: SNH inhibited all test strains with minimum inhibitory concentrations (MICs) ranging from 16 to 64 µg/mL in susceptibility tests, and displayed inhibition to bacterial growth in concentration-dependent manner in time-kill analysis. In synergy studies, the combinations of SNH-oxacillin, SNH-cephalothin, SNH-meropenem and SNH-netilmicin showed synergistic effects against 12 MRSA strains with median fractional inhibitory concentration (FIC) indices of 0.38, 0.38, 0.25 and 0.38 in checkerboard assays. In time-kill analysis, SNH at 1/2 MIC in combination with oxacillin at 1/128 to 1/64 MIC or netilmicin at 1/8 to 1/2 MIC decreased the viable colonies by ≥2log(10) CFU/mL. CONCLUSIONS/SIGNIFICANCE: SNH demonstrated in vitro antibacterial activity against 103 hospital-associated MRSA isolates. Combinations of sub-MIC levels of SNH and oxacillin or netilmicin significantly improved the in vitro antibacterial activity against MRSA compared with either drug alone. The SNH-based combinations showed promise in combating MRSA.
has issue date	2013-07-02(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0068053
bibo:pmid	23844154
has license	cc-by
sha1sum (hex)	f1541ead6bf6988b4d08b12873806a89a4b7ff1b
schema:url	https://doi.org/10.1371/journal.pone.0068053
resource representing a document's title	In Vitro Activity of Sodium New Houttuyfonate Alone and in Combination with Oxacillin or Netilmicin against Methicillin-Resistant Staphylococcus aureus
has PubMed Central identifier	PMC3699466
has PubMed identifier	23844154
schema:publication	PLoS One
resource representing a document's body	covid:f1541ead6bf6988b4d08b12873806a89a4b7ff1b#body_text
is schema:about of	named entity 'Staphylococcus aureus' named entity 'SEPSIS' named entity 'IN VITRO ACTIVITY' named entity 'NOVEL' named entity 'STAPHYLOCOCCUS AUREUS' named entity 'CAUSE' named entity 'INCLUDING' named entity 'EVALUATE' named entity 'BACKGROUND' named entity 'SEVERE' named entity 'HOUTTUYNIA CORDATA THUNB.' named entity 'ASSOCIATED' named entity 'NEW' named entity 'COMBINATION' named entity 'ANTIBIOTICS' named entity 'SODIUM' named entity 'METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS' named entity 'OXACILLIN' named entity 'HOSPITAL' named entity 'BACTEREMIA' named entity 'INFECTIONS' named entity 'INGREDIENT' named entity 'ANALOGUE' named entity 'TREATMENT OPTIONS' named entity 'IN VITRO ACTIVITY' named entity 'AIM' named entity 'HOUTTUYNIN' named entity 'SPREAD' named entity 'ITS' named entity 'MRSA' named entity 'NETILMICIN' named entity 'SODIUM' named entity 'MAIN' named entity 'SYNERGY' named entity 'POTENTIAL' named entity 'NEW' named entity 'NEED FOR' named entity 'STUDY' named entity 'ANTIBACTERIAL' covid:arg/f1541ead6bf6988b4d08b12873806a89a4b7ff1b named entity 'antibacterial' named entity 'MRSA' named entity 'severe infections' named entity 'antibacterial' named entity 'MRSA' named entity 'sepsis' named entity 'Staphylococcus aureus' named entity 'MIC' named entity 'microtiter plates' named entity 'MRSA' named entity 'MRSA' named entity 'antimicrobial agents' named entity 'MRSA' named entity 'antimicrobials' named entity 'antibacterial' named entity 'hydrophobic' named entity 'methicillin-susceptible Staphylococcus aureus' named entity 'Technology Development' named entity 'MRSA' named entity 'MRSA' named entity 'antibacterial' named entity 'MIC' named entity 'MRSA' named entity 'sodium' named entity 'oxacillin' named entity '99.9%' named entity 'MIC' named entity 'MRSA' named entity 'gram negative bacteria' named entity 'Southwest China' named entity 'antimicrobial agents' named entity 'Beijing' named entity 'CAMH'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software